FEBP1 protein vector host cells and method for making FEBP1 protein
AssigneeAventis Pharma S.A.
InventorsIsabelle Maury, Luc Mercken, Alain Fournier
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds and their pharmaceutical or diagnostic use, or use as a pharmacological target. More particularly, the present invention describes the identification of partners of the FE65 protein and the use of these partners, or of any compound which is capable of modulating, at least partially, their interaction with FE65, for regulating the activity of FE65, and in particular the phenomenon of intracellular transport or of endocytosis of the APP.
Claims26
Compound capable of modulating, at least partially, the interaction of the hnRNPL and/or FEBP1 proteins, or a homolog of these proteins, with the PTB1 domain of FE65.
Polypeptide comprising the sequence SEQ ID No. :9 or a derivative or fragment of this sequence.
Polypeptide comprising the sequence SEQ ID No. :7 or a derivative or fragment of this sequence.
Nonpeptide compound or a compound which is not exclusively of peptide nature, which is capable of modulating, at least partially, the interaction of the hnRNPL and/or FEBP1 proteins, or a homolog of these proteins, with the PTB1 domain of FE65.
Method for screening or characterizing active molecules, comprising a step of selecting molecules which are capable of binding the sequence SEQ ID No. 7 or the sequence SEQ ID No. 9, or a fragment of these sequences.
Dependencies are inferred from the claim text.